Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNAseq of pancreatas from KRasG12D/RosaMycER+/- or KRasG12D/RosaMycER+/+ treated with Tamoxifen for 12h

ABSTRACT: RNAseq of pancreatas from KRasG12D/RosaMycER+/- or KRasG12D/RosaMycER+/+ treated with Tamoxifen for 12h

PROVIDER: PRJEB46823 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR6434280.fastq.gz	Fastqsanger.gz
	ERR6434271.fastq.gz	Fastqsanger.gz
	ERR6434281.fastq.gz	Fastqsanger.gz
	ERR6434272.fastq.gz	Fastqsanger.gz
	ERR6434282.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

RNAseq of pancreatas from KRasG12D/RosaMycER+/- or KRasG12D/RosaMycER+/+ treated with Tamoxifen for 12h

Project description:Experiment designed to study the effect of 1 or 2 copies of deregulated myc on transcriptional profile during pancreatic cancer progression. In the KRasG12D/RosaMycER mouse model KRas and MycER are expressed exclusively in the pancreas, but MycER activity depends on Tamoxifen presence. RNAseq was preformed on pancreatas from KRasG12D/RosaMycER+/- or KRasG12D/RosaMycER+/+ mice treated 12 hours with Tamoxifen.

2022-06-08 | E-MTAB-10807 | biostudies-arrayexpress

RNAseq of cell line from pancreas from KRasG12D/RosaMycER mouse treated with Tamoxifen

Project description:Experiment designed to study the effect of deregulated myc on pancreatic cancer progression and regression. In the KRasG12D/RosaMycER mouse model KRas and MycER are expressed exclusively in the pancreas, but MycER activity depends on Tamoxifen presence. For this experiment a mouse was treated with Tamoxifen during 3 weeks, the pancreas was collected and the epithelial cells were grown in vitro in the presence of 4-OHT (4-Hydroxytamoxifen, active form of Tamoxifen). RNAseq were preformed on the cell line treated as follows: 1- 4-OHT all the time. 2- EtOH 6h. 3- EtOH 12h. 4- EtOH 18h.

2023-03-31 | E-MTAB-8693 | biostudies-arrayexpress

RNAseq of pancreata from KRasG12D/RosaMycER treated with Tamoxifen for different times

Project description:Experiment designed to study the effect of deregulated myc on pancreatic cancer progression and regression. In the KRasG12D/RosaMycER mouse model KRas and MycER are expressed exclusively in the pancreas, but MycER activity depends on Tamoxifen presence. RNAseq was preformed on pancreata from mice treated with Tamoxifen as follows: 1- Normal food. 2- Tamoxifen food 2 weeks. 3- Tamoxifen food 2 weeks, followed by normal food 1 day. 4- Tamoxifen food 2 weeks, followed by normal food 3 days.

2020-01-06 | E-MTAB-8467 | biostudies-arrayexpress

RNAseq of pancreatas from KRasG12D/RosaMycER treated with Tamoxifen for different times. MycOFF short times.

Project description:Experiment designed to study the effect of deregulated myc on pancreatic cancer progression and regression. In the KRasG12D/RosaMycER mouse model KRas and MycER are expressed exclusively in the pancreas, but MycER activity depends on Tamoxifen presence. RNAseq was preformed on pancreatas from mice treated with Tamoxifen as follows: 1-Tamoxifen food 2 weeks. 2- Tamoxifen food 2 weeks, followed by normal food 6 hours day. 3- Tamoxifen food 2 weeks, followed by normal food 12 hours.

2023-03-31 | E-MTAB-9564 | biostudies-arrayexpress

RNAseq of pancreata from KRasG12D/RosaMycER treated with Tamoxifen for different times

Project description:RNAseq of pancreata from KRasG12D/RosaMycER treated with Tamoxifen for different times

| PRJEB35067 | ENA

RNAseq of cell line from pancreas from KRasG12D/RosaMycER mouse treated with Tamoxifen

Project description:RNAseq of cell line from pancreas from KRasG12D/RosaMycER mouse treated with Tamoxifen

| PRJEB36308 | ENA

RNAseq of pancreatas from KRasG12D/RosaMycER treated with Tamoxifen for different times. MycOFF short times.

Project description:RNAseq of pancreatas from KRasG12D/RosaMycER treated with Tamoxifen for different times. MycOFF short times.

| PRJEB40319 | ENA

Next Generation Sequencing Facilitates Quantitative Analysis of pancreatic tissue transcriptomes from KrasG12D;Pdx1-Cre and miR-301a-/-;KrasG12D;Pdx1-Cre mice treated with caerulein

Project description:Purpose: we used next generation sequencing to analyze gene expression profiles of pancreatic tissues from KrasG12D;Pdx1-Cre and miR-301a-/-;KrasG12D;Pdx1-Cre mice treated with caerulein. The goals of this study are to compare the different gene expression profiles of pancreatic tissue between KrasG12D;Pdx1-Cre and miR-301a-/-;KrasG12D;Pdx1-Cre mice treated with caerulein.

2021-06-11 | GSE176571 | GEO

RNASeq of human breast cancer cells MCF7 and LCC2 treated with Tamoxifen or DMSO

Project description:RNASeq of human breast cancer cells MCF7 and LCC2 treated with Tamoxifen or DMSO

| PRJEB27236 | ENA

Expression data of Panc1 cells treated with romidepsin and tamoxifen

Project description:Tamoxifen enhances romidepsin-induced senescence in pancreatic cancer cells. We compared gene-expression profile among untreated control, romidepsin-treated, tamoxifen-treated, and romidepsin plus tamoxifen-treated Panc1 cells.

2021-08-21 | GSE182526 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data